Log in to search using one of your social media accounts:

 

Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan
Roche announced today that the phase III MURANO study, which evaluated Venclexta ®/Venclyxto® (venetoclax) in combination with MabThera®/Rituxan® (rituximab) in people with relapsed or refractory chronic lymphocytic leukaemia (CLL), met its primary endpoint and showed a statistically significant improvement in the time people lived without their disease progressing (progress ion-free survival [PFS] as assessed by investigator) when treated with Venclexta/Venclyxto plus MabThera/Rituxan compared to bendamustine plus Mabthera/Rituxan. (Source: Roche Media News)
Source: Roche Media News - September 18, 2017 Category: Pharmaceuticals Source Type: news

Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan
Roche announced today that the phase III MURANO study, which evaluated Venclexta ®/Venclyxto® (venetoclax) in combination with MabThera®/Rituxan® (rituximab) in people with relapsed or refractory chronic lymphocytic leukaemia (CLL), met its primary endpoint and showed a statistically significant improvement in the time people lived without their disease progressing (progress ion-free survival [PFS] as assessed by investigator) when treated with Venclexta/Venclyxto plus MabThera/Rituxan compared to bendamustine plus Mabthera/Rituxan. (Source: Roche Investor Update)
Source: Roche Investor Update - September 18, 2017 Category: Pharmaceuticals Source Type: news

Verastem improves progression-free survival in Phase III trial for CLL and SLL
US-based biopharmaceutical firm Verastem has reported positive top-line results from the Phase III DUO clinical trial of duvelisib to treat relapsed or refractory chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL). (Source: Drug Development Technology)
Source: Drug Development Technology - September 7, 2017 Category: Pharmaceuticals Source Type: news

Sunesis starts dosing in Phase Ib/II trial of SNS-062 for B-cell malignancies
Sunesis Pharmaceuticals has started dosing patients in a Phase Ib/II clinical trial of SNS-062 to treat patients with B-cell malignancies such as chronic lymphocytic leukaemia (CLL), small lymphocytic leukaemia, Waldenstrom ’s macroglobulinemia and ma… (Source: Drug Development Technology)
Source: Drug Development Technology - July 18, 2017 Category: Pharmaceuticals Source Type: news

Adding Ublituximab to Ibrutinib Improves Relapsed CLL Response Rates
Adding the novel CD20 inhibitor ublituximab to ibrutinib offered improved response rates and greater depth of response over ibrutinib alone in patients with relapsed/refractory chronic lymphocytic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - June 23, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Hematologic Malignancies Leukemia & Lymphoma News Source Type: news

FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved Rituxan Hycela™ (rituximab and hyaluronidase human) for subcutaneous (under the skin) injection, for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), and previously untreated and previously treated chronic lymphocytic leukaemia (CLL). (Source: World Pharma News)
Source: World Pharma News - June 23, 2017 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers
Roche today announced new data from multiple studies of Venclexta ®/Venclyxto® (venetoclax), presented at the 22nd European Hematology Association (EHA) Annual Congress, 22-25 June, in Madrid. (Source: Roche Media News)
Source: Roche Media News - June 23, 2017 Category: Pharmaceuticals Source Type: news

Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers
Roche today announced new data from multiple studies of Venclexta ®/Venclyxto® (venetoclax), presented at the 22nd European Hematology Association (EHA) Annual Congress, 22-25 June, in Madrid. (Source: Roche Investor Update)
Source: Roche Investor Update - June 23, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers
Roche announced today that the US Food and Drug Administration (FDA) approved Rituxan Hycela ™ (rituximab and hyaluronidase human) for subcutaneous (under the skin) injection, for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), and previously untreated and previously treated chronic lymphocytic leukaemia (CLL). (Source: Roche Media News)
Source: Roche Media News - June 23, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers
Roche announced today that the US Food and Drug Administration (FDA) approved Rituxan Hycela ™ (rituximab and hyaluronidase human) for subcutaneous (under the skin) injection, for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), and previously untreated and previously treated chronic lymphocytic leukaemia (CLL). (Source: Roche Investor Update)
Source: Roche Investor Update - June 23, 2017 Category: Pharmaceuticals Source Type: news

CAR T Cell/Ibrutinib Combination May Improve CLL Response Rates
Despite immune-related adverse events, concurrent ibrutinib and anti-CD19 CAR T-cell therapy may improve response rates in patients with chronic lymphocytic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - June 11, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Hematology Leukemia & Lymphoma News Source Type: news

Truxima (rituximab) for the Treatment of Cancer
ruxima ™ (rituximab) is the first biosimilar monoclonal antibody (mAb) approved for the treatment of haematological cancers, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukaemia, and rheumatoid arthritis, as well… (Source: Drug Development Technology)
Source: Drug Development Technology - June 8, 2017 Category: Pharmaceuticals Source Type: news

Janssen reports positive follow-up data from Phase III trial of Imbruvica for CLL
Janssen-Cilag International (Janssen) has reported positive data from a four-year follow-up period of its Phase III RESONATE trial of Imbruvica (ibrutinib) to treat relapsed / refractory (R/R) chronic lymphocytic leukaemia (CLL) patients. (Source: Drug Development Technology)
Source: Drug Development Technology - June 6, 2017 Category: Pharmaceuticals Source Type: news

Data at ASCO Show Consistent Progression-Free Survival Benefit in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients Treated with Ibrutinib, Including Those with High-Risk Disease, with Up to Four Years of Follow-Up
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 5, 2017 Category: Pharmaceuticals Source Type: news

New Data Presented at ASCO 2017 Finds IMBRUVICA(R) (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia (CLL) Treatment than Chemotherapy Agent Chlorambucil in Treatment-Naïve Patients
IMBRUVICA effectively impacted cancerous cells while sparing non-cancerous white blood cells through one year of treatment This release corresponds to abstract #7524 NORTH CHICAGO, Ill., June 5, 2017 -- (Healthcare Sales & Marketing Network) -- IMBR... Biopharmaceuticals, Oncology AbbVie, IMBRUVICA, ibrutinib, chronic lymphocytic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 5, 2017 Category: Pharmaceuticals Source Type: news

Personalized cell therapy combination achieves complete remission in CLL patients
(University of Pennsylvania School of Medicine) Combining the kinase inhibitor ibrutinib with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to new research from the Perelman School of Medicine at the University of Pennsylvania and Penn's Abramson Cancer Center (ACC). The team will present the results from its pilot study of this combination therapy during the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract # 193355). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 31, 2017 Category: Cancer & Oncology Source Type: news

Reassessment of Anti-CD20 Therapy in Lymphoid Malignancies: Impact, Limitations, and New Directions
This review will highlight the survival impact that rituximab therapy has had on major lymphoid malignancies, such as diffuse large B-cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, and mantle cell lymphoma. We will also discuss alternative anti-CD20 monoclonal antibodies. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2017 Category: Cancer & Oncology Authors: Jonathan W. Friedberg, MD, MMSc Patrick M. Reagan, MD Tags: Hematologic Malignancies Leukemia & Lymphoma Oncology Journal Review Article Source Type: news

New blood cancer study with'outstanding' results
Research reveals'transformative outcomes'for patients with chronic lymphocytic leukemia. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 27, 2017 Category: Science Source Type: news

'Outstanding' results announced from new blood cancer study
(University of Leicester) Research led by University of Leicester and University Hospitals of Leicester NHS Trust reveals 'transformative outcomes' for patients with chronic lymphocytic leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 27, 2017 Category: Cancer & Oncology Source Type: news

How Time Zones May Affect Cancer Risk
WASHINGTON — Where you live within your time zone could be associated with a slightly increased risk of developing certain cancers that have been linked to disruptions of the biological clock, a new study suggests. People’s biological clocks can become out of whack — which scientists call “circadian disruption” — if they work the night shift, for example. Such disruptions have been linked to an increased cancer risk in shift workers, said Dr. Neil Caporaso, an epidemiologist at the National Cancer Institute and the lead author of the study. But the disruptions that shift workers experien...
Source: Healthy Living - The Huffington Post - April 5, 2017 Category: Consumer Health News Source Type: news

MEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer
SAN DIEGO, April 3, 2017 -- (Healthcare Sales & Marketing Network) -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced the appointment of Brian Drazba as Chief Financial Office... Biopharmaceuticals, Oncology, Personnel MEI Pharma, acute myeloid leukemia, chronic lymphocytic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 3, 2017 Category: Pharmaceuticals Source Type: news

FDA advisory committee unanimously recommends approval of Roche ’s subcutaneous rituximab for certain blood cancers
Roche announced today that the U.S. Food and Drug Administration ’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted unanimously (11 to 0) that the benefit-risk of rituximab/hyaluronidase for subcutaneous (under the skin) injection was favourable for the treatment of certain blood cancers, which include: previously untreated follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), relapsed or refractory low grade or follicular lymphoma, and previously untreated and relapsed or refractory chronic lymphocytic leukemia (CLL). (Source: Roche Investor Update)
Source: Roche Investor Update - March 30, 2017 Category: Pharmaceuticals Source Type: news

BeiGene begins dosing in Phase II trial of BGB-3111 for CLL / SLL treatment in China
BeiGene has begun dosing in a Phase II clinical trial of its investigational drug candidate BGB-3111 for the treatment of patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in China. (Source: Drug Development Technology)
Source: Drug Development Technology - March 13, 2017 Category: Pharmaceuticals Source Type: news

A 5-Question Quiz on Chronic Lymphocytic Leukemia
What conditions are associated with CLL development? What novel agent resulted in significantly better progression-free survival in all CLL settings? Test your knowledge in our latest quiz. (Source: CancerNetwork)
Source: CancerNetwork - March 5, 2017 Category: Cancer & Oncology Authors: Debra Hughes Tags: Quiz Source Type: news

Frontline CLL Therapy: Changes in Paradigm
Significant progress has been made in the treatment of chronic lymphocytic leukemia with the addition of options such as the tyrosine kinase inhibitor ibrutinib, the monoclonal antibody obinutuzumab, and the BCL2 inhibitor venetoclax. (Source: CancerNetwork)
Source: CancerNetwork - February 25, 2017 Category: Cancer & Oncology Authors: Kanti Rai, MD Tags: Hematologic Malignancies Conferences/ICHM 2017 Leukemia & Lymphoma Q Source Type: news

Mutations Tied to Ibrutinib Resistance in Leukemia Mutations Tied to Ibrutinib Resistance in Leukemia
In patients with chronic lymphocytic leukemia, mutations indicating acquired resistance to the Bruton tyrosine kinase (BTK) inhibitor ibrutinib may help guide therapy, researchers say. (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 22, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Genetically engineered T-cells treat leukemia in babies
[Image courtesy of Caroline Davis2010, per Creative Commons 2.0 license]Researchers in London have successfully treated leukemia in two babies, in what they are touting as the world’s first treatment of cancer using genetically engineered immune cells from donors. Two British infants, who were 11 and 16 months old, were treated using Cellectis’ CAR T-cell product, UCART19, which is an allogeneic CAR T-cell product candidate for the treatment of chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL). They had gone through previous radiation treatments that failed before being treated with Cell...
Source: Mass Device - February 17, 2017 Category: Medical Equipment Authors: Danielle Kirsh Tags: Biotech Research & Development immunotherapy leukemia Source Type: news

Reasons for Ibrutinib Discontinuation Linked With Length of CLL Survival
Patients with chronic lymphocytic leukemia who discontinue treatment with ibrutinib due to disease progression or transformation had significantly worse survival compared with patients who discontinued therapy because of intolerance. (Source: CancerNetwork)
Source: CancerNetwork - February 16, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Leukemia & Lymphoma News Source Type: news

Chemotherapy vs Ibrutinib for Frontline Treatment of Chronic Lymphocytic Leukemia
This video examines frontline treatment options for patients with newly diagnosed chronic lymphocytic leukemia, including considerations for when chemotherapy or ibrutinib might be more appropriate. (Source: CancerNetwork)
Source: CancerNetwork - February 8, 2017 Category: Cancer & Oncology Authors: Susan O ’Brien, MD Tags: Videos Hematologic Malignancies Source Type: news

Study links immune system genetic variants to development of leukaemia
A new study has found that people inheriting genetic variants affecting the function of their immune system are at risk of developing chronic lymphocytic leukaemia (CLL). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 7, 2017 Category: Pharmaceuticals Source Type: news

Venetoclax Plus Rituximab:'Unprecedented' Efficacy in CLL Venetoclax Plus Rituximab:'Unprecedented' Efficacy in CLL
A new chemo-free combination, venetoclax and rituximab, has shown complete response rates in half of patients with refractory or relapsed chronic lymphocytic leukemia (CLL).Medscape Medical News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - January 24, 2017 Category: Pathology Tags: Hematology-Oncology News Source Type: news

3 things to know about 2016 drug approvals
In 2016, the U.S. Food and Drug Administration ’s (FDA) Center for Drug Evaluation and Research (CDER)approved 22 new medicines to treat a broad range of illnesses for patients in need. These much-needed new treatments include medicines for multiple sclerosis, chronic lymphocytic leukemia, ovarian and bladder cancer and the very rare spinal muscular atrophy (SMA). (Source: The Catalyst)
Source: The Catalyst - January 6, 2017 Category: Pharmaceuticals Tags: Medicines in Development PhRMA Fact Check FDA Modernization Source Type: news

Invasive Squamous Cell Carcinoma of the Scalp and Calvarium Invasive Squamous Cell Carcinoma of the Scalp and Calvarium
This report describes utilizing a multidisciplinary approach for calvarial reconstruction in a patient with chronic lymphocytic leukemia and invasive squamous cell carcinoma of the scalp.ePlasty, Open Access Journal of Plastic Surgery (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 5, 2017 Category: Consumer Health News Tags: Plastic Surgery & Aesthetic Medicine Journal Article Source Type: news

New Cancer Drug Approvals From 2016
Chemotherapy is one of the most powerful tools we have to treat cancer, and research continues to find new chemotherapy drugs as well as new uses for existing ones. At the same time, newer types of drugs are continually being developed that work in different ways to attack cancer cells.They include targeted therapy, which aims to more precisely identify cancer cells while doing less damage to normal cells, and immunotherapy, which uses the body’s own immune system to help find and destroy cancer.Before any new drug can be sold in the United States, it has to go through an approval process by the Food and Drug Adminis...
Source: American Cancer Society :: News and Features - December 26, 2016 Category: Cancer & Oncology Tags: Advanced Cancer Source Type: news

Outlook for 2017: Acute Leukemias, MDS, and CLL
This look ahead at hematologic malignancies in 2017 focuses on new agents being studied for the treatment of acute leukemias, myelodysplastic syndromes, and chronic lymphocytic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - December 26, 2016 Category: Cancer & Oncology Authors: Guido Marcucci, MD Tanya Siddiqi, MD Tags: Conferences/Hematologic Malignancies Year in Review 2016 Source Type: news

MorphoSys begins Phase II COSMOS trial of MOR208 combined with idelalisib to treat CLL or SLL
German biotechnology company MorphoSys has initiated its Phase II COSMOS trial of MOR208 combined with idelalisib (Zydelig) to treat adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). (Source: Drug Development Technology)
Source: Drug Development Technology - December 14, 2016 Category: Pharmaceuticals Source Type: news

Roche announces European approval of Venclyxto for people with hard-to-treat chronic lymphocytic leukaemia
Roche announced today that the European Commission has granted conditional marketing approval for Venclyxto ™ (venetoclax) for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in people who are unsuitable for or have failed a B-cell receptor pathway inhibitor; and for the treatment of CLL without 17p deletion or TP53 mutation in people who have failed both chemo-immunotherapy and a B-cell receptor pathway inhibitor. (Source: Roche Investor Update)
Source: Roche Investor Update - December 8, 2016 Category: Pharmaceuticals Source Type: news

Janssen-Cilag reports long-term follow-up data from Phase III RESONATE-2 trial of Ibrutinib to treat CLL
Janssen-Cilag has reported positive long-term follow-up results from its Phase III RESONATE-2 trial of Ibrutinib to treat chronic lymphocytic leukaemia (CLL). (Source: Drug Development Technology)
Source: Drug Development Technology - December 6, 2016 Category: Pharmaceuticals Source Type: news

Drug combination yields results in patients with forms of leukemia or lymphoma
(Dana-Farber Cancer Institute) A combination of two targeted agents -- one approved by the Food and Drug Administration and one undergoing testing -- has demonstrated safety as well as encouraging signs of effectiveness in a phase 1 clinical trial in patients with relapsed or hard-to-treat chronic lymphocytic leukemia or mantle cell lymphoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 5, 2016 Category: Cancer & Oncology Source Type: news

Predicting Disease Progression in CLL Patients on Ibrutinib
In this interview we discuss prognostic models that may be able to predict disease progression in patients with chronic lymphocytic leukemia treated with the targeted agent ibrutinib. (Source: CancerNetwork)
Source: CancerNetwork - December 3, 2016 Category: Cancer & Oncology Authors: Inhye E. Ahn, MD Tags: Conferences/ASH 2016 Hematologic Malignancies Leukemia & Lymphoma Source Type: news

CD19-targeting CAR T-cell immunotherapy yields high responses in treatment-resistant CLL
In a small, early phase trial, a high percentage of patients who had exhausted most traditional treatments for chronic lymphocytic leukemia saw their tumors shrink or even disappear after an infusion of a highly targeted, experimental CAR T-cell immunotherapy. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 3, 2016 Category: Science Source Type: news

CD19-targeting CAR T-cell immunotherapy yields high responses in treatment-resistant CLL
(Fred Hutchinson Cancer Research Center) In a small, early phase trial, a high percentage of patients who had exhausted most traditional treatments for chronic lymphocytic leukemia saw their tumors shrink or even disappear after an infusion of a highly targeted, experimental CAR T-cell immunotherapy developed at Seattle's Fred Hutchinson Cancer Research Center. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 3, 2016 Category: Global & Universal Source Type: news

New insight into why leukemia drug is successful
At the moment, chronic lymphocytic leukemia (CLL) is incurable. But in recent years, new drugs called B-cell receptor (BCR) inhibitors, have revolutionized treatment. Research now sheds light on why and how a new class of drug is effective at fighting off leukemia. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 29, 2016 Category: Science Source Type: news

UK ’s NICE recommends Janssen’s Imbruvica as treatment for adults with CLL
UK ’s National Institute for Health and Care Excellence (NICE) has published its final appraisal determination (FAD) recommending Janssen’s Imbruvica (ibrutinib), as a treatment option for adults with chronic lymphocytic leukaemia (CLL). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - November 29, 2016 Category: Pharmaceuticals Source Type: news

Costly leukemia pill wins UK green light after price cut
LONDON (Reuters) - A costly blood cancer pill sold in Europe by Johnson& Johnson will be made routinely available to certain patients in Britain with chronic lymphocytic leukemia, after the U.S. company agreed to cut the price. (Source: Reuters: Health)
Source: Reuters: Health - November 25, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Targeted therapy drugs could radically increase the costs of leukemia treatment
(Massachusetts General Hospital) A study by a Massachusetts General Hospital-led research team finds that, at current prices, adoption of novel oral targeted therapies for treatment of chronic lymphocytic leukemia could raise the treatment costs for the blood-system cancer in the US by almost 600 percent. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 21, 2016 Category: Cancer & Oncology Source Type: news

The Next Generation of Targeted Molecules for the Treatment of Chronic Lymphocytic Leukemia
This article describes the clinical data that led to approval of these B-cell receptor inhibitors for the treatment of CLL, and highlights newer agents in clinical development that target the same kinases as the currently available therapies. (Source: CancerNetwork)
Source: CancerNetwork - November 15, 2016 Category: Cancer & Oncology Authors: Deepa Jeyakumar, MD Susan O ’Brien, MD Tags: Hematologic Malignancies Conferences/Hematologic Malignancies Year in Review 2016 Leukemia & Lymphoma Oncology Journal Review Article Source Type: news

Living With Cancer: Chronic lymphocytic leukemia
  Chronic lymphocytic leukemia: An overview Chronic lymphocytic leukemia is a type of cancer of the blood and bone marrow that most commonly affects older adults. Learn about?causes, symptoms and treatment options. Workshop to help empower cancer patients, families The Mayo Clinic Cancer Education Program is offering a patient and family education symposium on Nov. [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - October 27, 2016 Category: Databases & Libraries Source Type: news

TKIs or Chemoimmunotherapy for Frontline CLL Management?
Clinicians and patients now have several options for frontline management of chronic lymphocytic leukemia; exactly which option is preferred remains up for debate. (Source: CancerNetwork)
Source: CancerNetwork - October 3, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Hematologic Malignancies Leukemia & Lymphoma Conferences/NCCN 2016 Source Type: news